Haier Biomedical: Planning Major Asset Restructuring

GoldenOctober2024

Jinshi data, December 27 news, Haier Biology announced that the company is planning to absorb Shanghai Laisi through Haier Biology to all shareholders of Shanghai Laisi by issuing A shares and raising supporting funds by issuing A shares. Due to the planned major asset restructuring, the company’s securities have been suspended from trading since the opening of the market on December 23, 2024, and the suspension is expected to last no more than 10 trading days. As of the date of this announcement, the company and related parties are actively advancing the relevant work of this transaction.

View Original
Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to Disclaimer.
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)